Otsuka wins FDA approval for Simtriyo ADHD treatment in adults, children 6+

PUBT · 1d ago
Otsuka wins FDA approval for Simtriyo ADHD treatment in adults, children 6+
  • Otsuka won FDA clearance for SIMTRIYO (centanafadine) to treat ADHD in adults, children aged 6+ weighing at least 20 kg.
  • Drug is positioned as the first approved norepinephrine, dopamine, serotonin reuptake inhibitor for ADHD.
  • US launch is slated for later this year, pending DEA scheduling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otsuka Holdings Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607242125BIZWIRE_USPR_____20260724_BW968244) on July 25, 2026, and is solely responsible for the information contained therein.